Sign in
Taking people in United StatesNo phase

Studying Fat-Tissue Immune Cells in Obesity and Lean Adults

Studies fat-tissue immune cells and fat metabolism in adults with obesity.

Key facts

Who runs it
Bettina Mittendorfer
Where
Columbia, United StatesSee the site
Trial code
Registry title
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
Status
Recruiting
People taking part
60 people, planned
Started
1 Aug 2024
Expected to end
Mar 2028
Type of study
Interventional, 4 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Dietary consultation weight loss intervention
Record updated
6 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 70, either lean or living with obesity. It studies fat tissue immune cells and how they handle fat.

Age
18 to 70 years
Sex
All sexes
Disease stage
Four groups: lean (BMI 18.5 to under 25.0), metabolically normal obesity, metabolically abnormal obesity with insulin resistance and fatty liver, and metabolically abnormal obesity with type 2 diabetes. Obesity groups have BMI 30.0 to under 45.0.
Earlier treatment
People cannot use medications or supplements that affect glucose and lipid metabolism. The exception is certain diabetes medicines in the type 2 diabetes group.
Biomarker or test result
Group-specific tests: liver fat (IHTG), fasting blood glucose, blood glucose 2 hours after a 75 g sugar drink, and HbA1c.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Weight not stable or not sedentary before enrollment
  • Use of tobacco products or too much alcohol
  • Significant organ disease, such as severe chronic kidney disease or cancer
  • Not meeting all inclusion criteria

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • age: ≥18 but ≤70 years
  • not pregnant or breastfeeding
  • weight stable and sedentary before enrollment
  • no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity [MAO]-Type 2 Diabetes group)
  • no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)
  • participants must fulfil all of the following group-specific inclusion criteria below:; Lean group:
  • Body mass index (BMI) ≥18.5 but <25.0 kg/m2
  • Intrahepatic triglyceride (IHTG) content <5%
  • fasting blood glucose concentration: <100 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl
  • Hemoglobin A1C (HbA1c) <5.7 %; Metabolically normal obesity (MNO) group:
  • BMI ≥30.0 but <45.0 kg/m2
  • IHTG content <5%
  • fasting blood glucose concentration: <100 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl
  • HbA1c <5.7 %; Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:
  • BMI ≥30.0 but <45.0 kg/m2
  • IHTG content >7.5%
  • fasting blood glucose concentration: ≥100 but <126 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but <200 mg/dl
  • HbA1c: ≥5.7 but <6.4 %; MAO-type 2 diabetes group:
  • BMI ≥30.0 but <45.0 kg/m2
  • clinical diagnosis of type 2 diabetes or fasting blood glucose concentration >126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge>200 mg/dl or HbA1c >6.4 % without medication if not diagnosed and medically treated for diabetes

Who cannot take part

  • Individuals that do not meet all inclusion Criterion

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • University of Missouri School of MedicineColumbia, United StatesContact: Bettina MittendorferTaking people

About the trial

What the trial wants to find out

The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.

Read full original descriptionShow less

Both groups will have:

* screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging [MRI] and magnetic resonance spectroscopy [MRS] scans) * Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies Participants with obesity will complete meetings with study team members for a weight loss intervention to achieve a 10% body weight loss.

The 4 groups in the trial

  • Lean IndividualsNo study treatment, for comparison

    No intervention will be administered.

  • Metabolically abnormal obese Individuals (obesity with normoglycemia and abnormal liver fat content)Treatment being tested

    Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.

    Treatment: Dietary consultation weight loss intervention

  • Metabolically normal obese Individuals (obesity with normoglycemia and normal liver fat content)Treatment being tested

    Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.

    Treatment: Dietary consultation weight loss intervention

  • Individuals with Type 2 Diabetes MellitusTreatment being tested

    Participants will undergo a dietary weight loss intervention to achieve 10% weight loss over about 6 months.

    Treatment: Dietary consultation weight loss intervention

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity-Associated Diseases
Plain-language title
Studying Fat-Tissue Immune Cells in Obesity and Lean AdultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06335771, who can take part
Record updated
6 August 2026